Axogen maintains 2026 revenue outlook of at least $290M after strong Q3 (AXGN:NASDAQ)

Axogen Inc (AXGN) reported Q3 EPS of $0.21, beating estimates by $0.08, with revenue at $75.8M, exceeding expectations. The company forecasts FY 2026 revenue of $290M, higher than analyst consensus. AXGN's stock is down 11.25% over 3 months but up 68.36% year-over-year.

Axogen, Inc. (AXGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Axogen, Inc. Reports Third Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million ALACHUA and TAMPA, FL – October 28, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical

Axogen, Inc. raised its 2026 revenue outlook to at least $290M, marking a 29% growth. The company expects $7M from BioCircuit, with organic revenue of at least $283M and a gross margin of 73% or more. Axogen also anticipates positive free cash flow for the year, according to the company.

Axogen reported Q3 2026 revenue of $75.8M, up 26% YoY, with adjusted net income of $13.1M. The company raised its 2026 revenue guidance to at least $290M and completed a $225M public offering and the BioCircuit acquisition. Gross margin decreased to 74.8% from 76.6% YoY.

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Barclays initiated coverage on Axogen with an Overweight rating and a $55 price target. The rating is based on valuation, EPS revisions, and visibility. Axogen's stock is currently trading at $36.31, down 2.44% over 5 days and 14.44% year-to-date.